Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Product sales, net	$ 2,059,284	$ 2,215,699	$ 7,566,848	$ 6,564,969
Cost of products sold	555,850	762,964	2,284,730	2,749,160
Gross profit	1,503,434	1,452,735	5,282,118	3,815,809
Selling, general and administrative expenses	2,823,765	3,283,378	9,834,781	9,681,326
Research and development expenses	170,478	166,191	524,472	897,218
Depreciation and amortization expense	15,896	16,661	49,798	50,121
Total operating expenses	3,010,139	3,466,230	10,409,051	10,628,665
Loss from operations	(1,506,705)	(2,013,495)	(5,126,933)	(6,812,856)
Interest income	30,600	28,012	102,669	26,819
Loss before provision for income taxes	(1,476,105)	(1,985,483)	(5,024,264)	(6,786,037)
Provision for income taxes	0	0	0	0
Net loss	(1,476,105)	(1,985,483)	(5,024,264)	(6,786,037)
Net loss attributable to noncontrolling interests	(9,811)	(13,680)	(33,987)	(54,030)
Net loss attributable to Milestone Scientific Inc.	$ (1,466,294)	$ (1,971,803)	$ (4,990,277)	$ (6,732,007)
Net loss per share applicable to common stockholders—
Basic and Diluted (in dollars per share)	$ (0.02)	$ (0.03)	$ (0.07)	$ (0.1)
Weighted average shares outstanding and to be issued—
Basic and Diluted (in shares)	73,730,921	70,975,420	72,374,693	70,480,706